Clinical trial
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast…
NCT00039780 · BioNumerik Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00039780 |
|---|---|
| Title | Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel |
| Official title | BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer |
| Lead sponsor | BioNumerik Pharmaceuticals, Inc., Industry |
| Collaborators | Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019. |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Breast Diseases, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | BNP7787, Placebo |
| Enrollment | 764 |
| Start date | Sep 1, 2001 |
| Primary completion | Oct 1, 2006 |
| Completion | Sep 1, 2014 |
| First posted | Jun 13, 2002 |
| Last update posted | Jul 13, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: